C4 Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 5, 2026, disclosing operational details, risk factors, and share count information for the third quarter.
Key Highlights
- Share count: As of October 30, 2026, the company had 131,317,488 shares of common stock, $0.0001 par value per share, outstanding.
- Filer status: The company is classified as a non-accelerated filer and a smaller reporting company, and is not an emerging growth company.
- Active collaborations: The filing identifies ongoing collaboration agreements with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co., Ltd., and Merck KGaA, Darmstadt, Germany.
- Clinical stage: The company disclosed it is a clinical-stage biopharmaceutical company and "has incurred significant losses since our inception."
- Funding risk: The company stated it "will need substantial additional funding to pursue our business objectives and continue our operations."
- Profitability outlook: The company disclosed it "expects to incur losses over at least the next several years and may never achieve or maintain profitability."
C4 Therapeutics Q3 2026: Clinical Stage Operations and Key Risk Disclosures
C4 Therapeutics, Inc. (NASDAQ:CCCC), headquartered at 490 Arsenal Way, Suite 120, Watertown, MA 02472, submitted its quarterly report covering the period ended September 30, 2026. According to the filing, the company operates as a clinical-stage biopharmaceutical company developing product candidates through its TORPEDO platform. The report notes active collaboration agreements with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively referred to in the filing as "Roche"), Betta Pharmaceuticals Co., Ltd. ("Betta Pharma"), and Merck KGaA, Darmstadt, Germany ("MKDG").
The filing discloses that as of October 30, 2026, there were 131,317,488 shares of common stock outstanding at a par value of $0.0001 per share. The company disclosed it is classified as a non-accelerated filer and a smaller reporting company under SEC rules, and confirmed it is not a shell company. The registrant's Commission File Number is 001-39567.
Among the risk factors summarized in the filing, the company stated that it has "incurred significant losses since our inception" and expects to continue incurring losses "over at least the next several years," with the possibility that it "may never achieve or maintain profitability." The filing also warns that if the company is "unable to raise capital when needed," it "may be required to delay, limit, reduce or terminate" research or product development programs or future commercialization efforts. The filing contains forward-looking statements that, according to the company, are subject to known and unknown risks and uncertainties, and the company notes these statements represent its views only as of the date of the filing.
What Was Disclosed
C4 Therapeutics filed its September 30, 2026 quarterly report disclosing 131,317,488 shares outstanding as of October 30, 2026, its clinical-stage status, active collaborations with Roche, Betta Pharma, and MKDG, and risk factors centered on funding needs and ongoing net losses.



Please wait processing your request...